The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months

Jay M. Sosenko; Jay S. Skyler; Craig A. Beam; David Boulware; Jeffrey L. Mahon; Jeffrey P. Krischer; Carla J. Greenbaum; Lisa E. Rafkin; Della Matheson; Kevan C. Herold; Jerry P. Palmer

doi:10.2337/dc14-2787

The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months

Jay M. Sosenko, Jay S. Skyler, Craig A. Beam, David Boulware, Jeffrey L. Mahon, Jeffrey P. Krischer, Carla J. Greenbaum, Lisa E. Rafkin, Della Matheson, Kevan C. Herold, Jerry P. Palmer

Medicine

Research output: Contribution to journal › Article

8 Scopus citations

Abstract

OBJECTIVE: We developed a scale to serve as a potential end point for 6-month glycemic progression (PS6M) toward type 1 diabetes (T1D) in autoantibody-positive relatives of individuals with T1D. RESEARCH DESIGN AND METHODS: The PS6M was developed from Diabetes Prevention Trial-Type 1 (DPT-1) data and tested in the TrialNet Pathway to Prevention Study (PTP). It is the difference between 6-month glucose sum values (30-120 min oral glucose tolerance test values) and values predicted for nonprogressors. RESULTS: The PS6M predicted T1D in the PTP (P < 0.001). The area under the receiver operating chacteristic curve was greater (P < 0.001) for the PS6M than for the baseline-to-6-month difference. PS6M values were higher in those with two or more autoantibodies, 30-0 min C-peptide values <2.00 ng/mL, or DPT-1 Risk Scores >7.00 (P < 0.001 for all). CONCLUSIONS: The PS6M is an indicator of short-term glycemic progression to T1D that could be a useful tool for assessing preventive treatments and biomarkers.

Original language	English (US)
Pages (from-to)	940-942
Number of pages	3
Journal	Diabetes care
Volume	38
Issue number	5
DOIs	https://doi.org/10.2337/dc14-2787
State	Published - May 2015

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Advanced and Specialized Nursing

Access to Document

10.2337/dc14-2787

Fingerprint Dive into the research topics of 'The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months'. Together they form a unique fingerprint.

Cite this

Sosenko, J. M., Skyler, J. S., Beam, C. A., Boulware, D., Mahon, J. L., Krischer, J. P., Greenbaum, C. J., Rafkin, L. E., Matheson, D., Herold, K. C., & Palmer, J. P. (2015). The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months. Diabetes care, 38(5), 940-942. https://doi.org/10.2337/dc14-2787

The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months. / Sosenko, Jay M.; Skyler, Jay S.; Beam, Craig A.; Boulware, David; Mahon, Jeffrey L.; Krischer, Jeffrey P.; Greenbaum, Carla J.; Rafkin, Lisa E.; Matheson, Della; Herold, Kevan C.; Palmer, Jerry P.

In: Diabetes care, Vol. 38, No. 5, 05.2015, p. 940-942.

Research output: Contribution to journal › Article

Sosenko, Jay M. ; Skyler, Jay S. ; Beam, Craig A. ; Boulware, David ; Mahon, Jeffrey L. ; Krischer, Jeffrey P. ; Greenbaum, Carla J. ; Rafkin, Lisa E. ; Matheson, Della ; Herold, Kevan C. ; Palmer, Jerry P. / The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months. In: Diabetes care. 2015 ; Vol. 38, No. 5. pp. 940-942.

@article{709ac6de3dbc4d85a76b69a009029a40,

title = "The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months",

abstract = "OBJECTIVE: We developed a scale to serve as a potential end point for 6-month glycemic progression (PS6M) toward type 1 diabetes (T1D) in autoantibody-positive relatives of individuals with T1D. RESEARCH DESIGN AND METHODS: The PS6M was developed from Diabetes Prevention Trial-Type 1 (DPT-1) data and tested in the TrialNet Pathway to Prevention Study (PTP). It is the difference between 6-month glucose sum values (30-120 min oral glucose tolerance test values) and values predicted for nonprogressors. RESULTS: The PS6M predicted T1D in the PTP (P < 0.001). The area under the receiver operating chacteristic curve was greater (P < 0.001) for the PS6M than for the baseline-to-6-month difference. PS6M values were higher in those with two or more autoantibodies, 30-0 min C-peptide values <2.00 ng/mL, or DPT-1 Risk Scores >7.00 (P < 0.001 for all). CONCLUSIONS: The PS6M is an indicator of short-term glycemic progression to T1D that could be a useful tool for assessing preventive treatments and biomarkers.",

author = "Sosenko, {Jay M.} and Skyler, {Jay S.} and Beam, {Craig A.} and David Boulware and Mahon, {Jeffrey L.} and Krischer, {Jeffrey P.} and Greenbaum, {Carla J.} and Rafkin, {Lisa E.} and Della Matheson and Herold, {Kevan C.} and Palmer, {Jerry P.}",

year = "2015",

month = may,

doi = "10.2337/dc14-2787",

language = "English (US)",

volume = "38",

pages = "940--942",

journal = "Diabetes Care",

issn = "1935-5548",

publisher = "American Diabetes Association Inc.",

number = "5",

}

TY - JOUR

T1 - The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months

AU - Sosenko, Jay M.

AU - Skyler, Jay S.

AU - Beam, Craig A.

AU - Boulware, David

AU - Mahon, Jeffrey L.

AU - Krischer, Jeffrey P.

AU - Greenbaum, Carla J.

AU - Rafkin, Lisa E.

AU - Matheson, Della

AU - Herold, Kevan C.

AU - Palmer, Jerry P.

PY - 2015/5

Y1 - 2015/5

N2 - OBJECTIVE: We developed a scale to serve as a potential end point for 6-month glycemic progression (PS6M) toward type 1 diabetes (T1D) in autoantibody-positive relatives of individuals with T1D. RESEARCH DESIGN AND METHODS: The PS6M was developed from Diabetes Prevention Trial-Type 1 (DPT-1) data and tested in the TrialNet Pathway to Prevention Study (PTP). It is the difference between 6-month glucose sum values (30-120 min oral glucose tolerance test values) and values predicted for nonprogressors. RESULTS: The PS6M predicted T1D in the PTP (P < 0.001). The area under the receiver operating chacteristic curve was greater (P < 0.001) for the PS6M than for the baseline-to-6-month difference. PS6M values were higher in those with two or more autoantibodies, 30-0 min C-peptide values <2.00 ng/mL, or DPT-1 Risk Scores >7.00 (P < 0.001 for all). CONCLUSIONS: The PS6M is an indicator of short-term glycemic progression to T1D that could be a useful tool for assessing preventive treatments and biomarkers.

AB - OBJECTIVE: We developed a scale to serve as a potential end point for 6-month glycemic progression (PS6M) toward type 1 diabetes (T1D) in autoantibody-positive relatives of individuals with T1D. RESEARCH DESIGN AND METHODS: The PS6M was developed from Diabetes Prevention Trial-Type 1 (DPT-1) data and tested in the TrialNet Pathway to Prevention Study (PTP). It is the difference between 6-month glucose sum values (30-120 min oral glucose tolerance test values) and values predicted for nonprogressors. RESULTS: The PS6M predicted T1D in the PTP (P < 0.001). The area under the receiver operating chacteristic curve was greater (P < 0.001) for the PS6M than for the baseline-to-6-month difference. PS6M values were higher in those with two or more autoantibodies, 30-0 min C-peptide values <2.00 ng/mL, or DPT-1 Risk Scores >7.00 (P < 0.001 for all). CONCLUSIONS: The PS6M is an indicator of short-term glycemic progression to T1D that could be a useful tool for assessing preventive treatments and biomarkers.

UR - http://www.scopus.com/inward/record.url?scp=84958651977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958651977&partnerID=8YFLogxK

U2 - 10.2337/dc14-2787

DO - 10.2337/dc14-2787

M3 - Article

C2 - 25758770

AN - SCOPUS:84958651977

VL - 38

SP - 940

EP - 942

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 5

ER -